3-Fluoro-5-methylbenzonitrile | CAS:216976-30-6

We serve 3-Fluoro-5-methylbenzonitrile CAS:216976-30-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Fluoro-5-methylbenzonitrile

Chemical Name:3-Fluoro-5-methylbenzonitrile
CAS.NO:216976-30-6
Synonyms:5-fluoro-3-methylbenzenecarbonitrile; 
3-Fluoro-5-Methylbenzonitrile; 
3-cyano-5-fluorotoluene; 
3-fluoro-5-methyl-benzonitrile;
Molecular Formula:C8H6FN
Molecular Weight:135.13800
 
Physical and Chemical Properties:
Density:1.54;
Melting point:50-52oC;
Boiling point:83-85oC;
Flash point:75oF;
Index of Refraction:1.;
 
Specification:
Appearance:White to off-white powder
Purity(GC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis
 



Contact us for information like 3-Fluoro-5-methylbenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-fluoro-5-methyl-benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Fluoro-5-methylbenzonitrile Use and application,5-fluoro-3-methylbenzenecarbonitrile technical grade,usp/ep/jp grade.


Related News: This includes chemical APIs.(E)-3-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)acrylaldehyde manufacturer An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.5-fluoro-3-nitropyridin-2-amine supplier A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).2,3-Difluorobenzaldehyde vendor A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).